BBI Solutions, Cardiff, UK, has added to its product line of antibodies across such areas as bone metabolism, cardiac disease, growth factors, sepsis, and thyroid disease. The company has released vitamin D2 and D3 products to aid in the diagnosis and monitoring of vitamin D deficiency, a risk factor for osteomalacia, osteoporosis, rickets, and other diseases. In the area of cardiac disease, the company has launched procalcitonin antibodies for use in assays to monitor disease progression and the effectiveness of treatment, as well as NT-proBNP antibodies, used as biomarkers in the diagnosis of heart failure. All new antibodies have been tested in enzyme-linked immunosorbent assay or lateral-flow assay formats, with high specificity and sensitivity results. For more information, visit BBI Solutions.
May 22, 2017
May 25, 2020